The existence of a reciprocal regulation between SOX2 and GLI1 [31] (this study), which is involved in the transcriptional activation of genes involved in melanoma progression [34], highlights the therapeutic potential of targeting this axis to treat a subset of advanced melanomas expressing high levels of SOX2 and GLI1. This evidence concerns the gene GLI1 and melanoma.